On May 14, 2026, the U.S. Supreme Court temporarily paused a lower court ruling that had blocked telehealth prescriptions of the drug mifepristone nationwide. This action allows the continued use of the medication — a lifeline for millions of women facing unwanted or medically contraindicated pregnancy, especially in states that have severe limitations or outright bans on abortion.

Mifepristone, taken in tandem with misoprostol, has mitigated the potentially disastrous consequences of the 2022 Supreme Court decision in Dobbs v. Jackson Women’s Health Organization. The Dobbs decision overturned Roe v. Wade, the 1973 decision that legalized abortion in all 50 U.S. states.

Without the right to control their own bodies and decide whether and when to have children — not only in cases of rape or incest but at any time — women can never achieve genuine equality. The capitalist class profits handsomely from the second-class status of women in society. That’s why both Republican and Democratic politicians have undermined women’s right to choose since Roe became law.

EDITORIAL

Before Roe v. Wade, most women in the United States seeking to end a pregnancy either had to travel to one of the few states where abortion was legal or seek care outside the country. The only other alternative was to roll the dice with a back-alley abortionist, often someone without formal medical training working in unsterile conditions.

According to the Guttmacher Institute, illegal abortion accounted for 17 percent of all U.S. deaths related to pregnancy in 1965. And this is only the number actually reported.

The mifepristone/misoprostol combination is today the most common method of terminating first trimester pregnancy, accounting for two thirds of abortions. A quarter of patients obtain their prescriptions via telehealth appointments. The pill is also prescribed following a miscarriage to prevent dangerous — sometimes life-threatening — complications.

In 2021, in the midst of the pandemic, the Federal Drug Administration (FDA) revised its rules to allow women to seek abortion care by telehealth. As a number of states responded to the Dobbs decision the following year by passing legislation to restrict access to abortion, the FDA guidance protected the right of every woman, no matter where she lived, to make her own medical care — and life — decisions.

In 2025, the State of Louisiana challenged the new FDA guidance in federal court, arguing that the agency’s justifications for remotely dispensing mifepristone were based on flawed or nonexistent data. It also claimed that the new regulation had resulted in numerous illegal abortions in Louisiana and in the state paying thousands in Medicaid bills for women “harmed by mifepristone.”

Louisiana also argued that allowing providers to prescribe mifepristone online violated its right under the Dobbs decision to regulate abortion in the state, asking for an emergency ruling to reimpose the in-person rule. The 5^th Circuit Court of Appeals granted this bid. The Supreme Court stay puts this ruling on hold while Louisiana’s case proceeds in the lower courts. If Louisiana prevails, it would impact all 50 states, regardless of what abortion legislation is on the books.

More than 50 years after abortion became legal, this right is being curtailed — not for “safety” reasons, as the state of Louisiana claims — but as the result of an accelerated shift to the right in bourgeois politics attempting to push women back in the kitchen “where they belong.”

These moves come even though a solid majority — about 60 percent — of people in the United States favor legal abortion in most circumstances.

A ban on telehealth access to reproductive care would compound the already increasing difficulty that patients across the United States encounter when seeking any form of medical care today.

On average, new patients in the United States face wait times of 31 days before seeing a doctor; that time frame is even longer when it comes to seeing a specialist. The longest wait times are for women needing an appointment with an Ob/Gyn (obstetrician/gynecologist) — nearly 42 days.

That 7-week window is critical in early pregnancy, when the mifepristone/misoprostol combination is safest. Since it can be several weeks before a woman knows she is pregnant and the recommended time to administer the drugs is within the first 10 weeks of gestation, the inability to get an in-person appointment with a doctor can force her into seeking a surgical alternative — more costly, more risky, and more likely now to involve travel, sometimes hundreds of miles from home.

The consequences of a ban on telehealth access to abortion medication would also fall most heavily on working-class women, especially Black, Latina, and other women of color. Black women are already three times more likely to die from pregnancy-related complications than white women; reducing access to abortion would only increase that disparity.

“Telehealth … as we saw with COVID … can make the difference between getting timely care and no care at all,” says Regina Davis Moss, president and CEO of In Our Own Voice.

The FDA is currently reviewing safety issues regarding mifepristone, which has a 25-year track record. While misoprostol can be used on its own, it has slightly higher failure rate and worse side effects than when used in combination with mifepristone.

In the meantime, the May 14 Supreme Court decision to stay any action restricting telehealth access to mifepristone is, literally, a lifesaver.

Protests demanding that such access become permanent, before this case returns to the Supreme Court, will maximize the chances of preventing another setback to women’s rights.

If you appreciate this article, share it with friends and subscribe to World-Outlook (for free) by clicking on the link below.

Type your email in the box below and click on “SUBSCRIBE.” You will receive a notification in your in-box on which you will have to click to confirm your subscription.